<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10341826</article-id><article-id pub-id-type="pmcid-ver">PMC10341826.1</article-id><article-id pub-id-type="pmcaid">10341826</article-id><article-id pub-id-type="pmcaiid">10341826</article-id><article-id pub-id-type="pmid">37446053</article-id><article-id pub-id-type="doi">10.3390/ijms241310879</article-id><article-id pub-id-type="publisher-id">ijms-24-10879</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Theobromine and Its Metabolites in Reducing the Risk of Uric Acid Lithiasis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0647-4154</contrib-id><name name-style="western"><surname>Costa-Bauz&#225;</surname><given-names initials="A">Antonia</given-names></name><xref rid="af1-ijms-24-10879" ref-type="aff">1</xref><xref rid="c1-ijms-24-10879" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Calv&#243;</surname><given-names initials="P">Paula</given-names></name><xref rid="af1-ijms-24-10879" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hern&#225;ndez</surname><given-names initials="Y">Yumaira</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af2-ijms-24-10879" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5636-9139</contrib-id><name name-style="western"><surname>Grases</surname><given-names initials="F">F&#232;lix</given-names></name><xref rid="af1-ijms-24-10879" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Soleimani</surname><given-names initials="M">Manoocher</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-10879"><label>1</label>Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISBa), University of Balearic Islands, 07122 Palma de Mallorca, Spain; <email>paula.calvo@uib.es</email> (P.C.); <email>fgrases@uib.es</email> (F.G.)</aff><aff id="af2-ijms-24-10879"><label>2</label>Urology Service of Manacor Hospital, 07500 Manacor, Spain; <email>yhernandez@hmanacor.com</email></aff><author-notes><corresp id="c1-ijms-24-10879"><label>*</label>Correspondence: <email>antonia.costa@uib.es</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>24</volume><issue>13</issue><issue-id pub-id-type="pmc-issue-id">440664</issue-id><elocation-id>10879</elocation-id><history><date date-type="received"><day>08</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>23</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-15 04:25:09.553"><day>15</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-10879.pdf"/><abstract><p>Uric acid lithiasis accounts for about 10% of all types of renal lithiasis. The most common causes of uric acid lithiasis are low urinary pH, followed by high concentration of urinary uric acid, and low diuresis. Treatment of patients consists of alkalinization of urine, reducing the consumption of purine-rich foods, and administration of xanthine oxidase inhibitors, because there are no established therapeutic inhibitors of uric acid crystallization. We recently found that theobromine inhibited uric acid crystallization in vitro, and that the increased urinary level of theobromine following its oral consumption was associated with the prevention of uric acid crystallization. In this study, we evaluated the inhibitory effects of theobromine metabolites and other methylxanthine-related compounds on uric acid crystallization. We also measured the urinary concentrations of theobromine and its metabolites in samples from healthy individuals and patients with uric acid stones and compared the extent of uric acid supersaturation and uric acid crystal formation in these different samples. Theobromine and other methylxanthines that lacked a substituent at position 1 inhibited uric acid crystallization, but other methylxanthines did not have this effect. Individuals with clinical parameters that favored uric acid crystallization did not develop uric acid crystals when theobromine and its metabolites were in the urine at high levels. Thus, theobromine and its metabolites reduced the risk of uric acid lithiasis.</p></abstract><kwd-group><kwd>uric acid lithiasis</kwd><kwd>theobromine</kwd><kwd>methylxanthines</kwd><kwd>crystallization inhibitors</kwd><kwd>lithiasis risk</kwd></kwd-group><funding-group><award-group><funding-source>Ministerio de Ciencia e Innovaci&#243;n</funding-source><award-id>PID2019-104331RB-I00</award-id></award-group><award-group><funding-source>Agencia Estatal de Investigaci&#243;n</funding-source><award-id>MCIN/AEI/10.13039/501100011033</award-id></award-group><funding-statement>Grant PID2019-104331RB-I00 was funded by the Ministerio de Ciencia e Innovaci&#243;n, Agencia Estatal de Investigaci&#243;n, MCIN/AEI/10.13039/501100011033.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-10879"><title>1. Introduction</title><p>Renal lithiasis has a worldwide prevalence of about 10% [<xref rid="B1-ijms-24-10879" ref-type="bibr">1</xref>,<xref rid="B2-ijms-24-10879" ref-type="bibr">2</xref>,<xref rid="B3-ijms-24-10879" ref-type="bibr">3</xref>], and the prevalence has increased over time [<xref rid="B3-ijms-24-10879" ref-type="bibr">3</xref>,<xref rid="B4-ijms-24-10879" ref-type="bibr">4</xref>]. A 2008 study estimated that the prevalence of renal lithiasis in 2050 could exceed 30% in some geographic areas due to increases in ambient temperature [<xref rid="B5-ijms-24-10879" ref-type="bibr">5</xref>]. Kidney stones can have different compositions, and about 10% of them consist of uric acid (UA) [<xref rid="B6-ijms-24-10879" ref-type="bibr">6</xref>,<xref rid="B7-ijms-24-10879" ref-type="bibr">7</xref>,<xref rid="B8-ijms-24-10879" ref-type="bibr">8</xref>,<xref rid="B9-ijms-24-10879" ref-type="bibr">9</xref>]. A high percentage of patients with UA lithiasis also have comorbidities such as hyperglycemia, obesity, and metabolic syndrome [<xref rid="B8-ijms-24-10879" ref-type="bibr">8</xref>,<xref rid="B9-ijms-24-10879" ref-type="bibr">9</xref>,<xref rid="B10-ijms-24-10879" ref-type="bibr">10</xref>]. </p><p>There are different types of renal stones, and these different stones have different etiologies. Stone formation can be affected by metabolic factors, genetic factors, and lifestyle factors, including diet and drug use. Urinary alterations and physiochemical factors also affect the risk of crystallization. An important etiological factor is urinary supersaturation of compounds that readily crystallize.</p><p>The main etiologic factors associated with the development of UA stones are urinary pH below 5.5, hyperuricosuria (defined as 24 h urinary UA exceeding 750 mg/day in females and 800 mg/day in males), and low diuresis [<xref rid="B9-ijms-24-10879" ref-type="bibr">9</xref>,<xref rid="B11-ijms-24-10879" ref-type="bibr">11</xref>,<xref rid="B12-ijms-24-10879" ref-type="bibr">12</xref>]. These conditions have different possible causes but are generally related to lifestyle [<xref rid="B13-ijms-24-10879" ref-type="bibr">13</xref>]. For example, low fluid intake is the most common cause of low diuresis, and this leads to increased urinary UA concentration (values greater than 500 mg/L) and eventually supersaturation. The consumption of foods with abundant purines, such as red meat, fish, shellfish, and to a lesser extent legumes, can cause hyperuricosuria because the body&#8217;s catabolism of purine produces UA as the final product. Certain drugs that inhibit renal tubular reabsorption of UA or increase purine catabolism can also cause hyperuricosuria. Finally, a urinary pH below 5.5, which may be due to chronic diarrhea or high production of endogenous acids due to the consumption of a high-protein diet, also increases the risk for UA stones. However, many patients with UA lithiasis do not present with any of these characteristics, and recent studies found that patients with metabolic syndrome often present with a low urinary pH, regardless of diet [<xref rid="B10-ijms-24-10879" ref-type="bibr">10</xref>]. The use of certain drugs, such as thiazides or furosemide, also decreases the urinary pH [<xref rid="B14-ijms-24-10879" ref-type="bibr">14</xref>].</p><p>Although the major etiological factors associated with UA lithiasis are low urinary pH, followed by high urinary levels of UA, and low diuresis, many individuals who have elevated urinary UA levels or low urinary pH do not develop UA stones [<xref rid="B15-ijms-24-10879" ref-type="bibr">15</xref>]. This indicates that other factors also affect the formation of these stones. In fact, the presence of certain kinetic factors can affect crystallization, and these include heterogeneous nucleants that facilitate crystallization and crystallization inhibitors [<xref rid="B16-ijms-24-10879" ref-type="bibr">16</xref>,<xref rid="B17-ijms-24-10879" ref-type="bibr">17</xref>].</p><p>The traditional treatments for UA lithiasis are alkalinization of urine, restricting the consumption of purine-rich foods, and pharmacological treatment with a xanthine oxidase inhibitor [<xref rid="B18-ijms-24-10879" ref-type="bibr">18</xref>]. In contrast to calcium lithiasis, there are no available therapeutic agents that inhibit the crystallization of UA. We recently found that theobromine, a dimethylxanthine alkaloid that is abundant in cocoa, inhibits UA crystallization [<xref rid="B19-ijms-24-10879" ref-type="bibr">19</xref>] and therefore may be useful for the prevention of UA lithiasis. In order to verify this usefulness, we carried out a comparative study of the treatment of UA lithiasis with citrate versus citrate+theobromine [<xref rid="B20-ijms-24-10879" ref-type="bibr">20</xref>]. In particular, our results confirmed that dietary theobromine increased urinary theobromine excretion, and that this was related to a decreased risk of UA crystallization. Nevertheless, the theobromine urinary concentrations found under citrate+theobromine treatment (0.102 &#177; 0.083 mmol/L) [<xref rid="B20-ijms-24-10879" ref-type="bibr">20</xref>] were in the low limit of efficacy (0.055 mmol/L) [<xref rid="B19-ijms-24-10879" ref-type="bibr">19</xref>], and for some patients, theobromine urinary concentrations were much lower than 0.055 mmol/L, which does not allow justification of the observed protective effect of theobromine against AU crystallization.</p><p>After intake of theobromine, the human body metabolizes it and excretes different products into the urine, mainly 7-methylxanthine (36%), unmetabolized theobromine (21%), 3-methylxanthine (21%), and 3,7-dimethyluric acid (1.3%) [<xref rid="B21-ijms-24-10879" ref-type="bibr">21</xref>]. </p><p>Thus, in order to better characterize the effects of methylxanthine consumption in the prevention of UA lithiasis, one objective of this study was to evaluate the inhibitory effects of theobromine metabolites and other methylxanthine-related compounds such as pentoxifylline (used as a drug to treat muscle pain in people with peripheral artery disease), dyphylline (used in the treatment of respiratory disorders such as asthma), and 7-(&#946;-hydroxyethyl)theophylline on UA crystallization in vitro. A second objective was to measure the urinary concentrations of theobromine and its metabolites in healthy individuals and in patients with UA stones, and to relate them to UA supersaturation and UA crystal formation in urine samples from these different individuals.</p></sec><sec sec-type="results" id="sec2-ijms-24-10879"><title>2. Results</title><sec id="sec2dot1-ijms-24-10879"><title>2.1. Turbidimetric Assay with Synthetic Urine Samples</title><p>We first measured the effect of the mixing time of synthetic urine with theobromine prior to the induction of UA supersaturation (<xref rid="ijms-24-10879-f001" ref-type="fig">Figure 1</xref>). The results demonstrated that the time needed for induction of UA crystals increased as the mixing time increased, but there was very little difference for mixing times of 15 min and 30 min.</p><p>The addition of 1-methylxanthine, pentoxifylline, 7-(&#946;-hydroxyethyl)theophylline, and dyphylline at concentrations of 0.60 mM had no significant effect on the time for induction of crystallization. However, under conditions of UA supersaturation (SS<sub>UA</sub> = 3.55), 0.60 mM 7-methylxanthine, 3,7-dimethyluric acid, and 3-methylxanthine inhibited crystallization; the first two of these compounds were about as effective as theobromine, but 3-methylxanthine had a weaker effect (<xref rid="ijms-24-10879-f002" ref-type="fig">Figure 2</xref>). </p><p>We then examined the effects of the combined presence of theobromine with two methylxanthines (3-methylxanthine and 7-methylxanthine) on the time for induction of UA crystallization (<xref rid="ijms-24-10879-f003" ref-type="fig">Figure 3</xref>). We did not test 3,7-dimethyluric acid because its level in urine is only 6% that of theobromine. The results showed that the combination of theobromine with 7-methylxanthine had a stronger effect, and this effect appeared to increase as the concentration of 7-methylxantine increased.</p><p>We then examined the effect of the different tested methylxanthines on morphology of UA crystals formed in artificial urine at pH 4.65. Scanning electron microscopy showed that the presence of all the methylxanthines altered the morphology of crystals, in that all obtained samples had thinner and longer crystals (<xref rid="ijms-24-10879-f004" ref-type="fig">Figure 4</xref>) in contrast with the crystals obtained in their absence, which had rectangular prism form. </p></sec><sec id="sec2dot2-ijms-24-10879"><title>2.2. Urine Samples from Healthy Individuals and Patients with UA Stones</title><p>We then applied the UA crystallization test (RUAC) in 60 urine samples from 20 healthy volunteers and 153 urine samples from 54 UA stone formers. There were 66 samples that had a risk for crystallization (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>A) and 147 samples that did not have a risk for crystallization (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>B). The results showed that only five samples with a risk for crystallization were false positive results (red in <xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>A), but thirty-four samples with no risk for crystallization were false negatives (red in <xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>B). These classifications were based on curves for saturation (SS<sub>UA</sub> = 1) and supersaturation (SS<sub>UA</sub> = 2) that were calculated as previously described [<xref rid="B8-ijms-24-10879" ref-type="bibr">8</xref>,<xref rid="B22-ijms-24-10879" ref-type="bibr">22</xref>].</p><p>We also measured the concentration of theobromine (<xref rid="ijms-24-10879-f006" ref-type="fig">Figure 6</xref>A) and of the sum of theobromine + 7-methylxanthine + 3,7-dimethyluric acid (<xref rid="ijms-24-10879-f006" ref-type="fig">Figure 6</xref>B; compounds with similar inhibitory effects on UA crystallization) of the 34 samples with false negative results.</p><p>Further analysis showed that the concentration of theobromine and its metabolites (7-methylxanthine and 3,7-dimethyluric acid) was nearly two-and-a-half times higher than the concentration of theobromine alone (<xref rid="ijms-24-10879-f007" ref-type="fig">Figure 7</xref>A) and that those samples with SS<sub>UA</sub> greater than two for which the UA crystallization test was negative had the highest urinary concentrations of theobromine and its metabolites, while those samples with SS<sub>UA</sub> lower than two for which the UA crystallization test was positive had the lowest ones (<xref rid="ijms-24-10879-f007" ref-type="fig">Figure 7</xref>B).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-24-10879"><title>3. Discussion</title><p>The obvious effect of mixing time prior to the induction of UA supersaturation on the inhibitory effects of theobromine (<xref rid="ijms-24-10879-f001" ref-type="fig">Figure 1</xref>) suggests that this inhibition is related to an interaction between theobromine and UA at the crystalline interface and in solution. In fact, a previous study of the molecular interactions between theobromine and UA in solution found that these molecules had a &#960;-stacking interaction [<xref rid="B23-ijms-24-10879" ref-type="bibr">23</xref>]. The formation of theobromine&#8211;UA clusters would decrease the supersaturation of UA and thus delay the formation of UA crystals. Our results demonstrated that the formation of UA crystals was delayed when the mixing time was 15 min or longer (<xref rid="ijms-24-10879-f001" ref-type="fig">Figure 1</xref>).</p><p>Our comparison of the effects of different methylxanthines showed theobromine, 7-methylxanthine, 3,7-dimethyluric acid, and 3-methylxanthine inhibited UA crystallization. However, none of the tested xanthine derivatives with substituents at position 1, 1-methylxanthine, pentoxifylline, 7-(&#946;-hydroxyethyl)theophylline, and dyphylline, were inhibitors of UA crystallization under the conditions studied. This finding agrees with previous results, which reported that caffeine, paraxanthine, and theophylline, each of which has a methyl group at position 1, do not inhibit UA crystallization [<xref rid="B19-ijms-24-10879" ref-type="bibr">19</xref>]. Moreover, we found that compounds with the greatest inhibition of UA crystallization had a methyl group at position 7. Thus, for xanthines, the positions of different substituent groups appear to affect the capacity to inhibit UA crystallization.</p><p>Two prospective clinical analyses of dietary risk factors for kidney stones found that caffeine consumption was inversely associated with this risk [<xref rid="B24-ijms-24-10879" ref-type="bibr">24</xref>,<xref rid="B25-ijms-24-10879" ref-type="bibr">25</xref>], even though caffeine itself does not inhibit UA crystallization. This may be because caffeine intake by humans leads to the urinary excretion of dimethylxanthines, methylxanthines, and dimethyl and methyluric acids [<xref rid="B26-ijms-24-10879" ref-type="bibr">26</xref>], and the total concentration of these metabolites is expected to be sufficient for inhibition of UA crystallization, based on the results presented herein.</p><p>Consumption of theobromine, which is abundant in cocoa, is excreted in the urine mainly as 7-methylxanthine (36%), unmetabolized theobromine (21%), 3-methylxanthine (21%), and 3,7-dimethyluric acid (1.3%) [<xref rid="B21-ijms-24-10879" ref-type="bibr">21</xref>], although these same compounds also occur in urine following caffeine consumption. For this reason, we tested the effects of mixtures of theobromine with 7-methylxanthine and 3-methylxanthine (<xref rid="ijms-24-10879-f003" ref-type="fig">Figure 3</xref>). The results showed that the total inhibitory effect was greater than or equal to the sum of the effects of each individual compound, with some evidence of synergistic effects at higher concentrations. Thus, UA crystallization in urine is affected by the global concentration of theobromine and several of its metabolites, especially 7-methylxanthine and 3,7-dimethyluric acid, which may also come from the metabolism of caffeine. </p><p>UA solubility obviously depends on pH (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>). Thus, solubility is below 110 mg/L for a urinary pH below 5.0, below 250 mg/L at pH 5.5, and higher than 600 mg/L for a pH over 6.0. Consequently, UA supersaturation in urine is a function of urinary pH as well as UA concentration [<xref rid="B8-ijms-24-10879" ref-type="bibr">8</xref>].</p><p>Crystal formation is only possible in a supersaturated solution (SS &gt; 1), although there is a range of supersaturation values at which a medium is metastable, in which crystals already formed can grow, but new crystals do not form. For supersaturation values above the upper limit of the metastable zone, the medium becomes unstable, and crystallization is spontaneous. For UA in urine, this limit corresponds to a SS<sub>UA</sub> level above 2 [<xref rid="B8-ijms-24-10879" ref-type="bibr">8</xref>,<xref rid="B22-ijms-24-10879" ref-type="bibr">22</xref>], even though certain factors can modify the kinetics of the process increasing the metastable range.</p><p>The risk of UA crystallization in urine samples, determined as explained above, was positive for samples with UA supersaturation values higher than 2 (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>A), and there was no risk of crystallization in samples with supersaturation values below 2 (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>B). However, we found that 34 of the 147 samples with no risk for UA crystallization had supersaturation values greater than 2; these samples should have crystallized, but they did not. Heterogeneous nucleants reduce the supersaturation value required for nucleation of new crystals. The presence of such factors in urine may explain why some of our samples developed UA crystals even when the SS<sub>UA</sub> was below 2 (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>A). However, this situation was not frequent (five of sixty-six samples).</p><p>Conversely, inhibitors of crystallization retard or impede one or more different steps of the crystallization process, and the presence of these inhibitors increases resistance to crystallization when the SS is above the metastable limit. This phenomenon seemed to be more common in our samples (<xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>B), indicating that many of our urine samples contained substances that prevented UA crystallization.</p><p>Analysis of the urinary theobromine concentration of samples in which UA crystallization did not occur when the supersaturation exceeded 2 showed that most of them had a theobromine concentration below 0.1 mM (<xref rid="ijms-24-10879-f006" ref-type="fig">Figure 6</xref>A). This is the lowest theobromine concentration at which there was inhibition of crystallization for UA supersaturation of 3.55. Nevertheless, the total concentration of theobromine and its metabolites was usually higher than 0.1 mM (<xref rid="ijms-24-10879-f006" ref-type="fig">Figure 6</xref>B). Thus, theobromine and its metabolites are likely responsible for preventing UA crystallization under these conditions. These results show that with a low intake of theobromine, crystallization inhibition values of the order of three times higher than expected, if only urinary theobromine concentration is considered, can be achieved. However, we have to consider that some samples with SS<sub>UA</sub> above 2 that had very low concentrations of theobromine and metabolites did not form UA crystals. This suggests that other heretofore unidentified inhibitors were also present in the urine samples.</p></sec><sec id="sec4-ijms-24-10879"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-24-10879"><title>4.1. Reagents and Solutions</title><p>UA, theobromine, 1-methylxanthine, 3-methylxanthine, 7-methylxanthine, 3,7-dimethyluric acid, pentoxifylline, 7-(&#946;-hydroxyethyl)theophylline, and dyphylline (<xref rid="ijms-24-10879-f008" ref-type="fig">Figure 8</xref>) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Synthetic urine components were obtained from Panreac (Montcada i Reixac, Barcelona, Spain). Chemicals of analytical reagent-grade purity were dissolved in ultra-pure deionized water from a Milli-Q system and passed through a 0.45 &#181;m filter before use. A UA stock solution (2 g/L) was prepared daily by dissolving 1 g of UA in 0.5 L of water, followed by addition of NaOH to achieve a final pH of 10.70. Synthetic urine (<xref rid="ijms-24-10879-t001" ref-type="table">Table 1</xref>) was prepared without calcium or oxalate to prevent calcium oxalate crystallization. The pH of the solution was adjusted to 5.40 before use.</p></sec><sec id="sec4dot2-ijms-24-10879"><title>4.2. Turbidimetric Assay</title><p>A previously described turbidimetric assay was used to determine the effect of theobromine and its metabolites on UA crystallization in an artificial urine medium, which contained 400 mg/L of UA and had a pH of 4.65 [<xref rid="B19-ijms-24-10879" ref-type="bibr">19</xref>]. These conditions correspond to supersaturation of UA (SS<sub>UA</sub> = 3.55). The turbidimetric system consisted of a photometer (AvaSpec-ULS2048CL-EVO, Avantes, The Netherlands) that was equipped with a fiber-optic light-guide measuring cell that was attached to a light path (2 &#215; 10 mm) reflector. Crystallization was assessed at a constant temperature (37 &#176;C) via mixing using a magnetic stir bar (300 rpm). </p><p>A stock solution of synthetic urine (80 mL) was added to a crystallization flask, followed by the addition of 80 mL of water and 40 mL of a 2 g/L UA solution. Then, 0.5 M HCl was added until the pH reached 4.65 to achieve UA supersaturation. This pH value was selected to ensure a short crystallization time (6&#8211;10 min without an inhibitor). Absorbance was recorded continuously to monitor crystal formation. </p><p>The studied compounds (<xref rid="ijms-24-10879-f008" ref-type="fig">Figure 8</xref>) were assayed at concentrations of 0.05 to 0.60 mM. These concentrations were achieved by adding an appropriate volume of a 2 mM solution of each compound to the crystallization mixture (with a corresponding reduction in the volume of added water) prior to the addition of HCl. This solution was mixed with a magnetic stir bar (300 rpm) for 15 min before induction of UA supersaturation. </p><p>Induction time (ti) was set as the time when the absorbance first began to increase. The effects of tested substances on the crystallization of UA were expressed as the increment of the induction time with respect to the induction time of the control (&#916; induction time). Each experiment was performed in triplicate.</p><p>For compounds that inhibited crystallization, the effects of different combinations were also determined.</p></sec><sec id="sec4dot3-ijms-24-10879"><title>4.3. Structural Analysis of Crystals</title><p>The morphologies of the UA crystals that formed in synthetic urine in the absence or presence of the different tested compounds were examined using a scanning electron microscopy system (SEM, Hitachi S-3400N, Tokyo, Japan) coupled with XR energy dispersive microanalysis (Bruker AXS XFlash Detector 4010, Berlin, Germany). Crystals were collected at the end of each experiment by passing the solution through a 0.45 &#181;m filter. They were then dried in a desiccator and examined using SEM by placing the crystals on a sample holder with fixation on adhesive conductive copper tape.</p></sec><sec sec-type="subjects" id="sec4dot4-ijms-24-10879"><title>4.4. Participants</title><p>Urine samples were provided by 20 healthy adult volunteers (11 males and 9 females, mean age: 37 years, age range: 22 to 65 years) and 54 volunteers who were active formers of UA stones (43 males and 11 females, mean age: 60 years, age range: 43 to 75 years). All volunteers were from Mallorca, Spain, and individuals with urinary infections were excluded. </p><p>The study design was approved by the local Ethics Investigation Committee of the Balearic Islands (IB 3475/17 PI) and by the Research Committee of Hospital Manacor and the Research Ethics Committee of Balearic Islands [CEI-IB] (IB3414). All participants provided written informed consent before participation. </p></sec><sec id="sec4dot5-ijms-24-10879"><title>4.5. Urine Samples</title><p>Three spot urine samples were collected from each participant at intervals of at least 7 days. Samples were collected under standard conditions in a sterile container, with no additives or preservatives, as they were processed immediately after collection. All participants were instructed to follow their usual diets. Patients with UA stones received oral theobromine (120 mg/day) for 14 days before collection of the third sample, and the results are included in a previously published study [<xref rid="B20-ijms-24-10879" ref-type="bibr">20</xref>] of dietary intervention to assess the efficacy of theobromine in UA stone prevention.</p><p>The main urinary parameters related to UA lithogenesis were determined. Thus, urinary pH was measured using a Crison pH meter, and UA concentration was determined using the uricase method. Theobromine and its metabolites were measured using ultra-high-performance liquid chromatography and high-resolution mass spectrometry (UHPLC/HRMS), as previously described [<xref rid="B27-ijms-24-10879" ref-type="bibr">27</xref>].</p><p>The urinary pH and UA concentrations were used to determine the UA supersaturation (SS<sub>UA</sub>) of a sample. As previously described [<xref rid="B20-ijms-24-10879" ref-type="bibr">20</xref>], the solubility (S) and SS<sub>UA</sub> were calculated using the following formulas at the pH of the sample:<disp-formula id="FD1-ijms-24-10879"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi>sp</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mtext>&#160;</mml:mtext><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>pH</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>HU</mml:mi></mml:mrow><mml:mo>&#8722;</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>&#8195;</mml:mo><mml:mo>&#8195;</mml:mo><mml:mo>&#8195;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>SS</mml:mi></mml:mrow><mml:mrow><mml:mi>UA</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mfenced><mml:mrow><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">U</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mfrac></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
where S (mol/L) and SS<sub>UA</sub> are at the pH of the sample, K<sub>sp</sub> is the solubility product of UA (2.25 &#215; 10<sup>&#8722;9</sup> mol<sup>2</sup>L<sup>&#8722;2</sup> at 37 &#176;C), K<sub>a1</sub> is the first dissociation constant of UA (4.2 &#215; 10<sup>&#8722;6</sup> mol/L at 37 &#176;C) [<xref rid="B28-ijms-24-10879" ref-type="bibr">28</xref>], <italic toggle="yes">&#947;</italic><sub>HU</sub>&#8722; is the monovalent ion activity coefficient of HU<sup>&#8722;</sup> at the characteristic ionic strength of urine (~0.75) [<xref rid="B29-ijms-24-10879" ref-type="bibr">29</xref>], and <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mfenced><mml:mrow><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">U</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> is the molar concentration of UA in the sample [<xref rid="B29-ijms-24-10879" ref-type="bibr">29</xref>]. </p></sec><sec id="sec4dot6-ijms-24-10879"><title>4.6. UA Crystallization Test</title><p>UA crystallization was determined by measuring the formation of UA crystals in polystyrene non-treated culture dishes (Corning, NY, USA), in which 5 mL of urine was maintained for 24 h at room temperature and then carefully removed via aspiration with a pipette. This test is a simplified version of the Risk for UA Crystallization (RUAC) test [<xref rid="B30-ijms-24-10879" ref-type="bibr">30</xref>]. A result was considered positive when UA crystals formed in the dish and negative when the dish contained no crystals (<xref rid="ijms-24-10879-f009" ref-type="fig">Figure 9</xref>).</p></sec><sec id="sec4dot7-ijms-24-10879"><title>4.7. Statistics</title><p>Intergroup comparisons (&#916; induction time between compounds) and intragroup comparisons (&#916; induction time between different concentrations of the same compound) were performed using a one-way ANOVA test. A two-tailed <italic toggle="yes">p</italic>-value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-24-10879"><title>5. Conclusions</title><p>Theobromine and other methylxanthines that lacked a substituent at position 1 inhibited UA crystallization, but other methylxanthines did not have this effect. Individuals with clinical parameters that favored UA crystallization did not develop UA crystals when theobromine and its metabolites were in the urine at high levels. Thus, theobromine and its metabolites reduced the risk of UA lithiasis.</p></sec></body><back><ack><title>Acknowledgments</title><p>P. Calv&#243; is grateful to the Conselleria d&#8217;Educaci&#243;, Universitat i Recerca of the Government of the Balearic Islands for the fellowship FPI_003_2020.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>A.C.-B.: Conceptualization, Methodology, Supervision, Writing&#8212;Original draft. P.C.: Investigation, Formal analysis, Writing&#8212;Original draft. Y.H.: Investigation, Resources. F.G.: Conceptualization, Methodology, Writing&#8212;Original draft. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Investigation Committee of the Balearic Islands (IB 3475/17 PI, approval 2017) and by the Research Committee of Hospital Manacor and the Research Ethics Committee of Balearic Islands [CEI-IB] (IB3414/17PI, approval 2017).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author [A.C.-B.], upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-24-10879"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>V.</given-names></name><name name-style="western"><surname>Akpinar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Assimos</surname><given-names>D.G.</given-names></name></person-group><article-title>Kidney stones: A global picture of prevalence, incidence, and associated risk factors</article-title><source>Rev. Urol.</source><year>2010</year><volume>12</volume><fpage>e86</fpage><lpage>e96</lpage><pub-id pub-id-type="doi">10.3909/riu0459</pub-id><pub-id pub-id-type="pmid">20811557</pub-id><pub-id pub-id-type="pmcid">PMC2931286</pub-id></element-citation></ref><ref id="B2-ijms-24-10879"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scales</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Saigal</surname><given-names>C.S.</given-names></name><collab>Urologic Diseases in America Project</collab></person-group><article-title>Prevalence of kidney stones in the United States</article-title><source>Eur. Urol.</source><year>2012</year><volume>62</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.03.052</pub-id><pub-id pub-id-type="pmid">22498635</pub-id><pub-id pub-id-type="pmcid">PMC3362665</pub-id></element-citation></ref><ref id="B3-ijms-24-10879"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatelou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>D.S.</given-names></name></person-group><article-title>Epidemiology of Kidney Stones</article-title><source>Healthcare</source><year>2023</year><volume>11</volume><elocation-id>424</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare11030424</pub-id><pub-id pub-id-type="pmid">36766999</pub-id><pub-id pub-id-type="pmcid">PMC9914194</pub-id></element-citation></ref><ref id="B4-ijms-24-10879"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chewcharat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curhan</surname><given-names>G.</given-names></name></person-group><article-title>Trends in the prevalence of kidney stones in the United States from 2007 to 2016</article-title><source>Urolithiasis</source><year>2021</year><volume>49</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s00240-020-01210-w</pub-id><pub-id pub-id-type="pmid">32870387</pub-id></element-citation></ref><ref id="B5-ijms-24-10879"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brikowski</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lotan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pearle</surname><given-names>M.S.</given-names></name></person-group><article-title>Climate-related increase in the prevalence of urolithiasis in the United States</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>9841</fpage><lpage>9846</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709652105</pub-id><pub-id pub-id-type="pmid">18626008</pub-id><pub-id pub-id-type="pmcid">PMC2474527</pub-id></element-citation></ref><ref id="B6-ijms-24-10879"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daudon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Jungers</surname><given-names>P.</given-names></name></person-group><article-title>Urinary calculi: Review of classification methods and correlations with etiology</article-title><source>Scanning Microsc.</source><year>1993</year><volume>7</volume><fpage>1081</fpage><lpage>1106</lpage><page-range>1081&#8211;1104; discussion 1104&#8211;1106</page-range><pub-id pub-id-type="pmid">8146609</pub-id></element-citation></ref><ref id="B7-ijms-24-10879"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name><name name-style="western"><surname>Costa-Bauz&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montesinos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>A.</given-names></name></person-group><article-title>Simple classification of renal calculi closely related to their micromorphology and etiology</article-title><source>Clin. Chim. Acta</source><year>2002</year><volume>322</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/s0009-8981(02)00063-3</pub-id><pub-id pub-id-type="pmid">12104078</pub-id></element-citation></ref><ref id="B8-ijms-24-10879"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiederkehr</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Moe</surname><given-names>O.W.</given-names></name></person-group><article-title>Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder</article-title><source>Clin. Rev. Bone Miner. Metab.</source><year>2011</year><volume>9</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/s12018-011-9106-6</pub-id><pub-id pub-id-type="pmid">25045326</pub-id><pub-id pub-id-type="pmcid">PMC4100778</pub-id></element-citation></ref><ref id="B9-ijms-24-10879"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakhaee</surname><given-names>K.</given-names></name></person-group><article-title>Epidemiology and clinical pathophysiology of uric acid kidney stones</article-title><source>J. Nephrol.</source><year>2014</year><volume>27</volume><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1007/s40620-013-0034-z</pub-id><pub-id pub-id-type="pmid">24497296</pub-id><pub-id pub-id-type="pmcid">PMC4696481</pub-id></element-citation></ref><ref id="B10-ijms-24-10879"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maalouf</surname><given-names>N.M.</given-names></name></person-group><article-title>Metabolic syndrome and the genesis of uric acid stones</article-title><source>J. Ren. Nutr.</source><year>2011</year><volume>21</volume><fpage>128</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1053/j.jrn.2010.10.015</pub-id><pub-id pub-id-type="pmid">21195936</pub-id><pub-id pub-id-type="pmcid">PMC3053068</pub-id></element-citation></ref><ref id="B11-ijms-24-10879"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Assimos</surname><given-names>D.G.</given-names></name></person-group><article-title>Uric Acid nephrolithiasis: Recent progress and future directions</article-title><source>Rev. Urol.</source><year>2007</year><volume>9</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">17396168</pub-id><pub-id pub-id-type="pmcid">PMC1831527</pub-id></element-citation></ref><ref id="B12-ijms-24-10879"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakhaee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adams-Huet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moe</surname><given-names>O.W.</given-names></name><name name-style="western"><surname>Pak</surname><given-names>C.Y.</given-names></name></person-group><article-title>Pathophysiologic basis for normouricosuric uric acid nephrolithiasis</article-title><source>Kidney Int.</source><year>2002</year><volume>62</volume><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00508.x</pub-id><pub-id pub-id-type="pmid">12164880</pub-id></element-citation></ref><ref id="B13-ijms-24-10879"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siener</surname><given-names>R.</given-names></name><name name-style="western"><surname>L&#246;hr</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>A.</given-names></name></person-group><article-title>Urinary risk profile, impact of diet, and risk of calcium oxalate urolithiasis in idiopathic uric acid stone disease</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>572</elocation-id><pub-id pub-id-type="doi">10.3390/nu15030572</pub-id><pub-id pub-id-type="pmid">36771279</pub-id><pub-id pub-id-type="pmcid">PMC9919786</pub-id></element-citation></ref><ref id="B14-ijms-24-10879"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bruijn</surname><given-names>P.I.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Frische</surname><given-names>S.</given-names></name><name name-style="western"><surname>Himmerkus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Praetorius</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Bleich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leipziger</surname><given-names>J.</given-names></name></person-group><article-title>Furosemide-induced urinary acidification is caused by pronounced H<sup>+</sup> secretion in the thick ascending limb</article-title><source>Am. J. Physiol. Ren. Physiol.</source><year>2015</year><volume>309</volume><fpage>F146</fpage><lpage>F153</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00154.2015</pub-id><pub-id pub-id-type="pmid">25995110</pub-id></element-citation></ref><ref id="B15-ijms-24-10879"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodgers</surname><given-names>A.L.</given-names></name></person-group><article-title>Urinary saturation: Casual or causal risk factor in urolithiasis?</article-title><source>BJU Int.</source><year>2014</year><volume>114</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1111/bju.12481</pub-id><pub-id pub-id-type="pmid">24119074</pub-id></element-citation></ref><ref id="B16-ijms-24-10879"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name><name name-style="western"><surname>Costa-Bauz&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>K&#246;nigsberger</surname><given-names>E.</given-names></name><name name-style="western"><surname>K&#246;nigsberger</surname><given-names>L.C.</given-names></name></person-group><article-title>Kinetic versus thermodynamic factors in calcium renal lithiasis</article-title><source>Int. Urol. Nephrol.</source><year>2000</year><volume>32</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1023/A:1007105328211</pub-id><pub-id pub-id-type="pmid">11057767</pub-id></element-citation></ref><ref id="B17-ijms-24-10879"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratkalkar</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>J.G.</given-names></name></person-group><article-title>Mechanisms of Stone Formation</article-title><source>Clin. Rev. Bone Miner. Metab.</source><year>2011</year><volume>9</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/s12018-011-9104-8</pub-id><pub-id pub-id-type="pmid">22229020</pub-id><pub-id pub-id-type="pmcid">PMC3252394</pub-id></element-citation></ref><ref id="B18-ijms-24-10879"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenny</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>D.S.</given-names></name></person-group><article-title>Update on the pathophysiology and management of uric acid renal stones</article-title><source>Curr. Rheumatol. Rep.</source><year>2010</year><volume>12</volume><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s11926-010-0089-y</pub-id><pub-id pub-id-type="pmid">20425021</pub-id></element-citation></ref><ref id="B19-ijms-24-10879"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costa-Bauza</surname><given-names>A.</given-names></name></person-group><article-title>Theobromine inhibits uric acid crystallization. A potential application in the treatment of uric acid nephrolithiasis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e111184</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111184</pub-id><pub-id pub-id-type="pmid">25333633</pub-id><pub-id pub-id-type="pmcid">PMC4205022</pub-id></element-citation></ref><ref id="B20-ijms-24-10879"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Costa-Bauza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calv&#243;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benejam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name></person-group><article-title>Comparison of two dietary supplements for treatment of uric acid renal lithiasis: Citrate vs. citrate + theobromine</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>2012</elocation-id><pub-id pub-id-type="doi">10.3390/nu12072012</pub-id><pub-id pub-id-type="pmid">32645831</pub-id><pub-id pub-id-type="pmcid">PMC7400936</pub-id></element-citation></ref><ref id="B21-ijms-24-10879"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodopoulos</surname><given-names>N.</given-names></name><name name-style="western"><surname>H&#246;jvall</surname><given-names>L.</given-names></name><name name-style="western"><surname>Norman</surname><given-names>A.</given-names></name></person-group><article-title>Elimination of theobromine metabolites in healthy adults</article-title><source>Scand. J. Clin. Lab. Investig.</source><year>1996</year><volume>56</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.3109/00365519609090590</pub-id><pub-id pub-id-type="pmid">8837245</pub-id></element-citation></ref><ref id="B22-ijms-24-10879"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lifshitz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Shalhav</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lingeman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Evan</surname><given-names>A.P.</given-names></name></person-group><article-title>Metabolic evaluation of stone disease patients: A practical approach</article-title><source>J. Endourol.</source><year>1999</year><volume>13</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1089/end.1999.13.669</pub-id><pub-id pub-id-type="pmid">10608520</pub-id></element-citation></ref><ref id="B23-ijms-24-10879"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattaraj</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name></person-group><article-title>Inclusion of Theobromine Modifies Uric Acid Aggregation with Possible Changes in Melamine-Uric Acid Clusters Responsible for Kidney Stones</article-title><source>J. Phys. Chem. B</source><year>2019</year><volume>123</volume><fpage>10483</fpage><lpage>10504</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.9b08487</pub-id><pub-id pub-id-type="pmid">31715106</pub-id></element-citation></ref><ref id="B24-ijms-24-10879"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraro</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Gambaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Curhan</surname><given-names>G.C.</given-names></name></person-group><article-title>Caffeine intake and the risk of kidney stones</article-title><source>Am. J. Clin. Nutr.</source><year>2014</year><volume>100</volume><fpage>1596</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.3945/ajcn.114.089987</pub-id><pub-id pub-id-type="pmid">25411295</pub-id><pub-id pub-id-type="pmcid">PMC4232021</pub-id></element-citation></ref><ref id="B25-ijms-24-10879"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chewcharat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thongprayoon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Schulte</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Lieske</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Rule</surname><given-names>A.D.</given-names></name></person-group><article-title>Dietary risk factors for incident and recurrent symptomatic kidney stones</article-title><source>Mayo Clin. Proc.</source><year>2022</year><volume>97</volume><fpage>1437</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2022.04.016</pub-id><pub-id pub-id-type="pmid">35933132</pub-id></element-citation></ref><ref id="B26-ijms-24-10879"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybak</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sternberg</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Pao</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>C.M.</given-names></name></person-group><article-title>Urine excretion of caffeine and select caffeine metabolites is common in the U.S. population and associated with caffeine intake</article-title><source>J. Nutr.</source><year>2015</year><volume>145</volume><fpage>766</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.3945/jn.114.205476</pub-id><pub-id pub-id-type="pmid">25833779</pub-id><pub-id pub-id-type="pmcid">PMC5724768</pub-id></element-citation></ref><ref id="B27-ijms-24-10879"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomila</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Martorell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Costa-Bauza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name></person-group><article-title>Quantification of xanthine- and uric acid-related compounds in urine using a &#8220;dilute-and-shoot&#8221; technique coupling ultra-high-performance liquid chromatography and high-resolution Orbitrap mass spectrometry</article-title><source>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</source><year>2017</year><volume>1067</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2017.09.047</pub-id><pub-id pub-id-type="pmid">28992566</pub-id></element-citation></ref><ref id="B28-ijms-24-10879"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name><name name-style="western"><surname>Villacampa</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Costa-Bauz&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#246;hnel</surname><given-names>O.</given-names></name></person-group><article-title>Uric acid calculi</article-title><source>Scanning Microsc.</source><year>1999</year><volume>13</volume><fpage>223</fpage><lpage>234</lpage></element-citation></ref><ref id="B29-ijms-24-10879"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coe</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tembe</surname><given-names>V.</given-names></name><name name-style="western"><surname>Le Dun</surname><given-names>S.</given-names></name></person-group><article-title>Uric acid saturation in calcium nephrolithiasis</article-title><source>Kidney Int.</source><year>1980</year><volume>17</volume><fpage>662</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/ki.1980.205</pub-id><pub-id pub-id-type="pmid">7401461</pub-id></element-citation></ref><ref id="B30-ijms-24-10879"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calv&#243;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Costa-Bauz&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grases</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sanchis</surname><given-names>P.</given-names></name></person-group><article-title>Validation of a novel diagnostic test for assessing the risk of urinary uric acid crystallization</article-title><source>Clin. Chim. Acta</source><year>2021</year><volume>519</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2021.05.001</pub-id><pub-id pub-id-type="pmid">33964262</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-10879-f001" orientation="portrait"><label>Figure 1</label><caption><p>Effect of the mixing time of synthetic urine with theobromine prior to the induction of UA supersaturation on the kinetics of UA crystallization followed by turbidimetry. A control sample was incubated without theobromine (a); other samples were incubated with 0.2 mM theobromine and were mixed for 0 min (b), 5 min (c), 15 min (d), or 30 min (e).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g001.jpg"/></fig><fig position="float" id="ijms-24-10879-f002" orientation="portrait"><label>Figure 2</label><caption><p>Effect of the concentration of theobromine and related methylxanthines on the induction time of UA crystallization in synthetic urine at pH 4.65. Induction times were obtained from crystallization curves (<xref rid="ijms-24-10879-f001" ref-type="fig">Figure 1</xref>), and all results are expressed as the increment of the induction time with respect to the induction time of the control (&#916; induction time) and are means of triplicates &#177; standard deviations. (a) Statistical differences between the different compounds at 0.2 mM concentration (<italic toggle="yes">p</italic> &lt; 0.05). (b) Statistical differences between 3MX and the other compounds at 0.4 mM concentration (<italic toggle="yes">p</italic> &lt; 0.05). (c) Statistical differences between 7MX and the other compounds at 0.6 M concentration. Tb: theobromine; 7MX: 7-methylxantine; 3MX: 3-methylxantine; 3,7DMUA: 3,7-dimethyluric acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g002.jpg"/></fig><fig position="float" id="ijms-24-10879-f003" orientation="portrait"><label>Figure 3</label><caption><p>Effect of the combination of theobromine with different methylxanthines on the induction time of UA crystallization in synthetic urine at pH 4.65. All results are expressed as the increment of the induction time with respect to the induction time of the control (&#916; induction time) and are means &#177; standard deviations of triplicates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g003.jpg"/></fig><fig position="float" id="ijms-24-10879-f004" orientation="portrait"><label>Figure 4</label><caption><p>Scanning electron microscopy of UA crystals formed in artificial urine collected after the turbidimetric assay. Top row: no additives; 0.60 mM of theobromine (Tb); 0.60 mM 7-methylxanthine (7MX); mixture of 0.4 mM Tb with 0.40 mM 7MX; bottom row: 0.60 mM 3,7-dimethyluric acid (3,7DMUA); 0.60 mM 3-methylxanthine (3MX); 0.60 mM 1-methylxanthine (1MX); or 0.60 mM paraxanthine (PX).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g004.jpg"/></fig><fig position="float" id="ijms-24-10879-f005" orientation="portrait"><label>Figure 5</label><caption><p>Urinary pH and UA concentration of individual urine samples, and UA saturation curves (SS<sub>UA</sub> = 1) and supersaturation curves (SS<sub>UA</sub> = 2). (<bold>A</bold>) Samples with positive UA crystallization results, with true positives in green and false positives in red. (<bold>B</bold>) Samples with negative UA crystallization results, with true negatives in green and false negatives in red.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g005.jpg"/></fig><fig position="float" id="ijms-24-10879-f006" orientation="portrait"><label>Figure 6</label><caption><p>Urinary theobromine concentration (<bold>A</bold>) and sum of theobromine, 7-methylxanthine, and 3,7-dimethyluric acid concentrations (<bold>B</bold>) in the 34 urine samples with SS<sub>UA</sub> greater than 2 for which the UA crystallization test was negative (See <xref rid="ijms-24-10879-f005" ref-type="fig">Figure 5</xref>B). Tb: theobromine; 7-MX: 7-methylxanthine; 3,7-DMUA: 3,7-dimethyluric acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g006.jpg"/></fig><fig position="float" id="ijms-24-10879-f007" orientation="portrait"><label>Figure 7</label><caption><p>Relationship of the concentration of theobromine with the concentration of theobromine and metabolites that had similar inhibitory effects on UA crystallization (<bold>A</bold>) and concentration of each compound (mean &#177; standard error of mean) in urine samples with different results for RUAC test and SS<sub>UA</sub> &gt; 2 or SS<sub>UA</sub> &lt; 2 (<bold>B</bold>). * Significant differences with the &#8220;RUAC positive with SS<sub>UA</sub> &gt; 2&#8221; group, <italic toggle="yes">p</italic> &lt; 0.005; # Significant differences with the &#8220;RUAC negative with SS<sub>AU</sub> &lt; 2&#8221; group, <italic toggle="yes">p</italic> &lt; 0.05. TB: theobromine; 7MX: 7-methylxanthine; 3MX: 3-methylxanthine; 3,7DMUA: 3,7-dimethyluric acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g007.jpg"/></fig><fig position="float" id="ijms-24-10879-f008" orientation="portrait"><label>Figure 8</label><caption><p>Chemical structures of theobromine, theobromine metabolites, and related methylxanthines: pentoxifylline (3,7-dimethyl-1-(5-oxohexyl)xanthine), dyphylline (7-(2,3-dihydroxypropyl)theophylline), and 7-(&#946;-hydroxyethyl)theophylline (1,3-dimethyl-7-(2-hydroxyethyl)xanthine). Note the presence or absence of different substituents at position 1 and the presence or absence of a methyl group at position 7 in the different molecules.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g008.jpg"/></fig><fig position="float" id="ijms-24-10879-f009" orientation="portrait"><label>Figure 9</label><caption><p>UA crystallization test results after incubation of 5 mL of different urine samples for 24 h. (<bold>A</bold>) No UA crystals (negative result); (<bold>B</bold>,<bold>C</bold>) UA crystals with typical orange color (positive results).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-10879-g009.jpg"/></fig><table-wrap position="float" id="ijms-24-10879-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-10879-t001_Table 1</object-id><label>Table 1</label><caption><p>Composition of the stock solution of synthetic urine (adjusted to pH 5.0). Synthetic urine samples were obtained by diluting 80 mL of stock solution to a final volume of 200 mL.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concentration (mM)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Na<sub>2</sub>SO<sub>4</sub>&#183;10H<sub>2</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.34</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MgSO<sub>4</sub>&#183;7H<sub>2</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>4</sub>Cl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KCl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">162.69</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaH<sub>2</sub>PO<sub>4</sub>&#183;2H<sub>2</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Na<sub>2</sub>HPO<sub>4</sub>&#183;12H<sub>2</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.64</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223.31</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>